XML 36 R20.htm IDEA: XBRL DOCUMENT
v3.21.2

Revenues (Tables) | 6 Months Ended
--- | ---
Jul. 02, 2021
Revenue from Contract with Customer [Abstract] |
Schedule of Disaggregation of Revenue | Revenues consisted of the following (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2021 |  | 2020 |  | 2021 |  | 2020 |  |
Product revenues: |  |  |  |  |  |  |  |  |
Gross product revenues | $ | 380,204 |  |  | $ | 229,898 |  |  | $ | 694,409 |  |  | $ | 482,464 |  |  |
Discounts and allowances | (95,956) |  |  | (51,168) |  |  | (182,949) |  |  | (109,854) |  |  |
Net product revenues | 284,248 |  |  | 178,730 |  |  | 511,460 |  |  | 372,610 |  |  |
Collaboration revenues: |  |  |  |  |  |  |  |  |
License revenues | 39,640 |  |  | 59,234 |  |  | 67,168 |  |  | 80,113 |  |  |
Collaboration services revenues | 61,289 |  |  | 21,515 |  |  | 76,779 |  |  | 33,671 |  |  |
Total collaboration revenues | 100,929 |  |  | 80,749 |  |  | 143,947 |  |  | 113,784 |  |  |
Total revenues | $ | 385,177 |  |  | $ | 259,479 |  |  | $ | 655,407 |  |  | $ | 486,394 |  |  |
Net product revenues by product were as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2021 |  | 2020 |  | 2021 |  | 2020 |  |
CABOMETYX | $ | 275,614 |  |  | $ | 173,610 |  |  | $ | 499,209 |  |  | $ | 362,826 |  |  |
COMETRIQ | 8,634 |  |  | 5,120 |  |  | 12,251 |  |  | 9,784 |  |  |
Net product revenues | $ | 284,248 |  |  | $ | 178,730 |  |  | $ | 511,460 |  |  | $ | 372,610 |  |  |
Schedule of Concentration Risks | The percentage of total revenues by customer who individually accounted for 10% or more of our total revenues were as follows:
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2021 |  | 2020 |  | 2021 |  | 2020 |  |
Ipsen Pharma SAS | 24 | % |  | 20 | % |  | 19 | % |  | 17 | % |  |
Affiliates of McKesson Corporation | 14 | % |  | 11 | % |  | 14 | % |  | 13 | % |  |
Affiliates of CVS Health Corporation | 13 | % |  | 13 | % |  | 14 | % |  | 15 | % |  |
Affiliates of AmerisourceBergen Corporation | 12 | % |  | 11 | % |  | 13 | % |  | 11 | % |  |
Affiliates of Optum Specialty Pharmacy | 8 | % |  | 10 | % |  | 9 | % |  | 11 | % |  |
Accredo Health, Incorporated | 8 | % |  | 10 | % |  | 8 | % |  | 9 | % |  |
Takeda Pharmaceutical Company Limited | 2 | % |  | 10 | % |  | 2 | % |  | 5 | % |  |
The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows:
| June 30, 2021 |  | December 31, 2020 |  |  |  |
Ipsen Pharma SAS | 24 | % |  | 23 | % |  |  |  |
Affiliates of McKesson Corporation | 21 | % |  | 12 | % |  |  |  |
Affiliates of AmerisourceBergen Corporation | 19 | % |  | 11 | % |  |  |  |
Affiliates of CVS Health Corporation | 13 | % |  | 11 | % |  |  |  |
Takeda Pharmaceutical Company Limited | 4 | % |  | 10 | % |  |  |  |
Schedule of Revenues Disaggregated by Geographic Region | Revenues by geographic region were as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2021 |  | 2020 |  | 2021 |  | 2020 |  |
U.S. | $ | 287,190 |  |  | $ | 181,231 |  |  | $ | 517,147 |  |  | $ | 377,827 |  |  |
Europe | 90,921 |  |  | 52,917 |  |  | 124,727 |  |  | 81,953 |  |  |
Japan | 7,066 |  |  | 25,331 |  |  | 13,533 |  |  | 26,614 |  |  |
Total revenues | $ | 385,177 |  |  | $ | 259,479 |  |  | $ | 655,407 |  |  | $ | 486,394 |  |  |
Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances | The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):
| Chargebacks, Discounts for Prompt Payment and Other |  | Other Customer Credits/Fees and Co-pay Assistance |  | Rebates |  |  |  | Total
Balance at December 31, 2020 | $ | 9,853 |  |  | $ | 3,279 |  |  | $ | 17,404 |  |  |  |  | $ | 30,536 |
Provision related to sales made in: |  |  |  |  |  |  |  |  |
Current period | 114,489 |  |  | 15,392 |  |  | 51,355 |  |  |  |  | 181,236 |
Prior periods | (40) |  |  | (164) |  |  | 1,917 |  |  |  |  | 1,713 |
Payments and customer credits issued | (108,487) |  |  | (11,637) |  |  | (46,349) |  |  |  |  | (166,473) |
Balance at June 30, 2021 | $ | 15,815 |  |  | $ | 6,870 |  |  | $ | 24,327 |  |  |  |  | $ | 47,012 |
Schedule of Other Assets and Other Liabilities | Contract assets and liabilities were as follows (in thousands):
| June 30, 2021 |  | December 31, 2020
Contract assets |  |  |
Current portion(1) | $ | 9,749 |  |  | $ | — |
Long-term portion(1) | 948 |  |  | — |
Total contract assets | $ | 10,697 |  |  | $ | — |
Contract liabilities: |  |  |
Current portion(2) | $ | 6,314 |  |  | $ | 1,790 |
Long-term portion(2) | 8,577 |  |  | 3,755 |
Total contract liabilities | $ | 14,891 |  |  | $ | 5,545 |
____________________ (1) Presented in prepaid and other current assets and other long-term assets, respectively, on the accompanying Condensed Consolidated Balance Sheets. (2) Presented in other current liabilities and long-term portion of deferred revenues, respectively, in the accompanying Condensed Consolidated Balance Sheets.

X
- Definition Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block] + References No definition available. + Details
Name: | exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
Namespace Prefix: | exel_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph a -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration